BioCentury | Oct 9, 2020
Finance

Kronos’ post-IPO gains build on $1B+ postmoney valuation

...gains were Shattuck Labs Inc. (NASDAQ:STTK) and Spruce Biosciences Inc....
...CD172a; SHPS-1) - Signal regulatory protein alpha Paul Bonanos Spruce Biosciences Inc. Shattuck...
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...million in March for its pipeline of TCR bispecifics (see “Immunocore’s $130M series B” ). Spruce Biosciences Inc....
...a principal at consulting firm Ceutec LLC, which he founded. Robin Sawka, BioCentury Staff Editas Medicine Inc. Immunocore Ltd. Spruce Biosciences Inc. Frazier...
BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

...hyperplasia (CAH). Omega Funds and Abingworth co-led the new $88 million series B round for Spruce Biosciences Inc....
...Targets ACTH - adrenocorticotropic hormone CRFR1 (CRHR1) - Corticotropin-releasing factor receptor 1 Paul Bonanos, Associate Editor SPR001 Spruce Biosciences Inc. tildacerfont...
BioCentury | Oct 13, 2017
Finance

Sprucely debut

...prepared for every eventuality,” he said. Amran Gowani, Senior Editor, Research & Analytics SPR001 Novo Holdings A/S RiverVest Venture Partners Spruce Biosciences Inc. congenital...
BioCentury | Oct 13, 2017
Financial News

Rare endocrine play Spruce emerges from stealth and announces $20M series A

...On Oct. 12, Spruce Biosciences Inc. (San Francisco, Calif.) revealed a $20 million series A round of funding...
...Novo’s Tiba Aynechi and RiverVest’s Niall O’Donnell joined Spruce's board. Spruce Biosciences Inc. , San Francisco, Calif. Meghan Sullivan SPR001 Spruce Biosciences Inc....
BioCentury | Oct 12, 2017
Financial News

Rare endocrine play Spruce emerges from stealth

...Grey, and CMO Michael Huang. Novo’s Tiba Aynechi and RiverVest’s Niall O’Donnell joined Spruce's board. Paul Bonanos SPR001 Spruce Biosciences Inc....
Items per page:
1 - 6 of 6
BioCentury | Oct 9, 2020
Finance

Kronos’ post-IPO gains build on $1B+ postmoney valuation

...gains were Shattuck Labs Inc. (NASDAQ:STTK) and Spruce Biosciences Inc....
...CD172a; SHPS-1) - Signal regulatory protein alpha Paul Bonanos Spruce Biosciences Inc. Shattuck...
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

...million in March for its pipeline of TCR bispecifics (see “Immunocore’s $130M series B” ). Spruce Biosciences Inc....
...a principal at consulting firm Ceutec LLC, which he founded. Robin Sawka, BioCentury Staff Editas Medicine Inc. Immunocore Ltd. Spruce Biosciences Inc. Frazier...
BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

...hyperplasia (CAH). Omega Funds and Abingworth co-led the new $88 million series B round for Spruce Biosciences Inc....
...Targets ACTH - adrenocorticotropic hormone CRFR1 (CRHR1) - Corticotropin-releasing factor receptor 1 Paul Bonanos, Associate Editor SPR001 Spruce Biosciences Inc. tildacerfont...
BioCentury | Oct 13, 2017
Finance

Sprucely debut

...prepared for every eventuality,” he said. Amran Gowani, Senior Editor, Research & Analytics SPR001 Novo Holdings A/S RiverVest Venture Partners Spruce Biosciences Inc. congenital...
BioCentury | Oct 13, 2017
Financial News

Rare endocrine play Spruce emerges from stealth and announces $20M series A

...On Oct. 12, Spruce Biosciences Inc. (San Francisco, Calif.) revealed a $20 million series A round of funding...
...Novo’s Tiba Aynechi and RiverVest’s Niall O’Donnell joined Spruce's board. Spruce Biosciences Inc. , San Francisco, Calif. Meghan Sullivan SPR001 Spruce Biosciences Inc....
BioCentury | Oct 12, 2017
Financial News

Rare endocrine play Spruce emerges from stealth

...Grey, and CMO Michael Huang. Novo’s Tiba Aynechi and RiverVest’s Niall O’Donnell joined Spruce's board. Paul Bonanos SPR001 Spruce Biosciences Inc....
Items per page:
1 - 6 of 6